{
    "clinical_study": {
        "@rank": "100678", 
        "acronym": "RASTS", 
        "arm_group": {
            "arm_group_label": "Tocilizumab", 
            "arm_group_type": "Other", 
            "description": "All subjects will receive tocilizumab."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to determine if a change in inflammation seen on the\n      ultrasound is a good indicator of how patients' rheumatoid arthritis is responding to the\n      TCZ and whether patients should be dose escalated earlier from 4 mg/kg to 8mg/kg."
        }, 
        "brief_title": "Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Patient must meet 1987 ACR criteria,\n\n          2. Age > 18 years of age,\n\n          3. Baseline DAS28/ESR>4.4,\n\n          4. Stable concomitant DMARDs,\n\n          5. Stable prednisone <10mg or equivalent, and\n\n          6. Power Doppler score of >=10"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717859", 
            "org_study_id": "ML28542", 
            "secondary_id": "ML28542"
        }, 
        "intervention": {
            "arm_group_label": "Tocilizumab", 
            "description": "All subjects will start at 4mg/kg. After 3 months, if DAS28 > 3.2, dosage will be escalated to 8 mg/kg.", 
            "intervention_name": "Tocilizumab", 
            "intervention_type": "Drug", 
            "other_name": "Actemra"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Rheumatoid Arthritis", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "UCLA David Geffen School of Medicine, Division of Rheumatology"
            }, 
            "investigator": {
                "last_name": "Veena K Ranganath, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab", 
        "overall_contact": {
            "email": "vranganath@mednet.ucla.edu", 
            "last_name": "Veena K Ranganath, M.D."
        }, 
        "overall_official": {
            "affiliation": "UCLA David Geffen School of Medicine, Division of Rheumatology", 
            "last_name": "Veena Ranganath, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "28 joints will be evaluated.", 
            "measure": "Change in total power Doppler synovitis score of 28 joints (range 0-42)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 1 Month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717859"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Los Angeles", 
            "investigator_full_name": "Dr. Veena Ranganath", 
            "investigator_title": "M.D., M.S., Assistant Clinical Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "28 joints will be evaluated.", 
                "measure": "Change in total B-mode synovial hypertrophy score of 28 joints (range 0-42)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1 Month"
            }, 
            {
                "description": "28 joints will be evaluated.", 
                "measure": "Change in composite of power Doppler + synovial hypertrophy of 28 joints (range 0-84)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1 Month"
            }
        ], 
        "source": "University of California, Los Angeles", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of California, Los Angeles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}